Autek China Inc
SZSE:300595
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
13.27
25.03
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Autek China Inc
Autek China Inc
Cash & Cash Equivalents
Autek China Inc
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Autek China Inc
SZSE:300595
|
Cash & Cash Equivalents
¥898.6m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
|
|
Shandong Weigao Group Medical Polymer Co Ltd
HKEX:1066
|
Cash & Cash Equivalents
¥7.5B
|
CAGR 3-Years
5%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
Autobio Diagnostics Co Ltd
SSE:603658
|
Cash & Cash Equivalents
¥349.1m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
Winner Medical Co Ltd
SZSE:300888
|
Cash & Cash Equivalents
¥4.7B
|
CAGR 3-Years
4%
|
CAGR 5-Years
66%
|
CAGR 10-Years
N/A
|
|
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
Cash & Cash Equivalents
¥1B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
Intco Medical Technology Co Ltd
SZSE:300677
|
Cash & Cash Equivalents
¥6.6B
|
CAGR 3-Years
7%
|
CAGR 5-Years
51%
|
CAGR 10-Years
N/A
|
|
Autek China Inc
Glance View
Ovctek China, Inc. engages in the operation of eye vision technology. The company is headquartered in Hefei, Anhui and currently employs 2,772 full-time employees. The company went IPO on 2017-01-17. The firm's main business is non-surgical vision correction. The firm's main products include orthokeratology, general contact lens and care products. Its core product is Dream David orthokeratology. In addition, The Company is also engaged in general glass frame sales business. The firm mainly operates its business in the domestic market.
See Also
What is Autek China Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
898.6m
CNY
Based on the financial report for Sep 30, 2024, Autek China Inc's Cash & Cash Equivalents amounts to 898.6m CNY.
What is Autek China Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
28%
Over the last year, the Cash & Cash Equivalents growth was -30%. The average annual Cash & Cash Equivalents growth rates for Autek China Inc have been -1% over the past three years , 28% over the past five years .
You don't have any saved screeners yet
